POGO

  • Staff List
  • Contact Us

Main menu

Skip to primary content
Skip to secondary content
  • About Us
    • Our Mission and Vision
    • Childhood Cancer Care Plan
    • POGO Land Acknowledgement
    • Diversity, Equity, Inclusion
    • Our Board
    • Our Partners
    • Our Donors
    • Privacy
    • Accessibility
    • Reports
    • Newsroom
    • Job Opportunities
    • Staff List
  • Programs & Support
    • Patient Care Programs
    • Financial Assistance
    • Survivor Care
    • Cancer Resources
    • Inspiring Stories
    • Clinical and Program Advisory Committees
  • Education
    • POGO Multidisciplinary Symposium on Childhood Cancer
    • POGO Virtual Education
    • Indigenous Resource Guide
    • All Education Events & Conferences
  • Healthcare Practice
    • COVID-19 Updates
    • Pediatric Oncology Nursing
    • Clinical Practice Guidelines
    • POGO Satellite Manual
  • Research & Data
    • 2020 POGO Surveillance Report
    • POGO Research Unit
    • POGONIS – Childhood Cancer Database
    • Data Reports
    • Data Requests
  • Get Involved
    • Pajamas and Pancakes
    • Birthday Parties for POGO
    • Events
    • Volunteer
  • Ways to Give
    • Donate
    • Gifts of Stock and Securities
    • Become a Corporate Partner
    • Gifts in Honour/Memory
    • Legacy Gifts
    • Shop Online/Earn Cash Back

Blog

POGO > Blog > Low-Grade Gliomas
[sharethis]

Tag: Low-Grade Gliomas


BRAF Inhibition and Fusion in Low Grade Glioma

Posted on November 22, 2018 by Jamie Irvine


VIEW THE PRESENTATION

Presentation Description:
The management of low grade gliomas is very complex disease. Treatment decisions can be based on the surgical resection, radiological response or progression, visual acuity/preservation, other associated morbidity. Essentially, low grade glioma is a chronic disease and most children will require more than one line of therapy. In the last 30 years clinicians have moved away from treating low grade gliomas with radiation and have used various modalities of chemotherapy to treat these tumours. MEK and BRAF inhibitors have shown excellent promise and response in the Low grade glioma and NF1 population but their length of therapy and side effect management is quite different then “regular” chemotherapy. This presentation will provide a brief overview of low grade glioma’s and highlight the new emerging treatment with BRAF and MEK inhibitors along with the management of the side effects associated with these medications.

Speaker:
Tara McKeown, RN MN NP-Paediatrics
Nurse Practitioner Neuro-oncology Team
The Hospital for Sick Children

Adjunct Lecturer, Lawrence S. Bloomberg, Faculty of Nursing, University of Toronto Tara McKeown completed a Bachelor of Science degree at the University of Western Ontario and then went on to complete a Bachelor of Science in Nursing at the University of Toronto. She worked at the Hospital for Sick Children inpatient Haematology/Oncology inpatient ward as a Registered Nurse for five years and during that time completed a Master of Nursing with Nurse Practitioner in the child stream. Tara has worked as the Nurse Practitioner with the Neuro Oncology team at the Hospital for Sick Children since Jan 2013. She also retains adjunct appointment as an Adjunct Lecturer for the Lawrence S. Bloomberg Faculty of Nursing at the University of Toronto. Tara has worked closely with the New Agents and Innovative Therapy team at Sick Kids as new drugs, treatments and side effect management is emerging for the Neuro Oncology population.

Posted in 2018 Pre-Symposium Nursing Seminar | Tagged 2018 pre-symposium, Low-Grade Gliomas, nursing

Brain Teaser: Optic and Other Low-Grade Gliomas

Posted on August 2, 2013 by admin

Presentation Description: Paediatric low grade gliomas (LGG) account for the largest group of intracranial and spinal tumours in childhood. When resection is possible, cure can be achieved by surgery only. The management of unresectable LGG is still unsatisfactory. Traditionally radiation was the standard treatment for these tumours. However, over the last 2 decades, multiple protocols of chemotherapy have been tested, and they have all demonstrated that chemotherapy can induce tumour shrinkage. Unfortunately, in the long term, only 30-40% of treated patients show sustained tumour control. This means that a majority of LGG patients will require more than one treatment.

This presentation provides an overview of the current knowledge, recent advances and future direction in the management of paediatric LGG.

Speaker:

Eric Bouffet, MD, FRCP(C)
Director, Pediatric Neuro-Oncology Program
The Hospital for Sick Children
Professor of Pediatrics
University of Toronto, Toronto, ON

 

Posted in 2013 Satellite Education Day, Education for Health Professionals | Tagged 2013 satellite education day, chemotherapy, Low-Grade Gliomas

Telomere Maintenance in Pediatric Neuronal Tumors: Hope for a Better Ending?

Posted on February 5, 2013 by admin

Presentation Description: The ability of tumors to divide endlessly is one of the hallmarks of cancer.  Telomere maintenance is the main mechanism by which tumor cells achieve this goal.  This session examined how by using the unique model of pediatric low grade gliomas and neuroblastomas which tend to undergo spontaneous growth arrest, the role of telomere maintenance in these tumors can be defined, which can lead to the development of potential novel therapies to treat high grade pediatric gliomas and neuroblastomas.

Speaker:

Uri Tabori, MD
Neuro-Oncologist, Division of Hematology/Oncology
The Hospital for Sick Children, Toronto, ON
Assistant Professor of Pediatrics
Institute of Medical Sciences, University of Toronto, Toronto, ON
Scientist, Genetic and Genomic Biology
The Research Institute and the Arthur and Sonia Labatt Brain tumor Research Centre, The Hospital for Sick Children, Toronto, ON

Posted in 2009 Symposium, Education for Health Professionals | Tagged 2009 Symposium, brain tumors, Low-Grade Gliomas, neuroblastoma, telomere maintenance

Low-Grade Glioma – Where Is It Headed?

Posted on February 5, 2013 by admin

Presentation Description: Low-Grade Gliomas (LGG) account for the largest group of childhood brain tumors, representing approximately one third of childhood brain tumors.  LGG are usually slow growing, although for reasons that are not completely clear, some of these tumors may show aggressive behavior and/or have erratic growth rates, particularly in young children with hypothalamic/chiasmatic gliomas.  Surgery is the treatment of choice for resectable tumors and is often curative in these instances.  However, a large number of LGG arise in areas where the role of surgery is limited, due to the morbidity associated with attempts at aggressive resection.  Radiation therapy to such tumors has demonstrated evidence of benefit, with objective radiographic responses often for long periods of time, although the use of radiation therapy in young children often results in serious long-term sequelae.  It is now clear that chemotherapy can delay or obviate the need for radiation therapy. Over the past decade, the upfront use of chemotherapy has become standard therapy for children and infants with unresectable tumors.  This presentation provided an overview of strategies in pediatric LGG, with an emphasis on chemotherapeutic management.

Speaker:

Eric Bouffet, MD
Professor of Paediatrics
University of Toronto, Toronto, ON
Head, Neuro-Oncology section, Division of Haematology/Oncology
The Hospital for Sick Children, Toronto, ON

Posted in 2009 Symposium, Education for Health Professionals | Tagged 2009 Symposium, brain tumors, Low-Grade Gliomas

Donate

Blog

Education Portal
Survivor Conference
All Categories

Categories

Newsletter Sign-Up

Please leave this field empty

@POGO4Kids

August 10, 2022

We are thrilled to share our 2022 Impact Report —demonstrating the power donors have and how their generosity has made a significant impact on the #childhoodcancercare community. Thank you. https://www.pogo.ca/about-us/reports/

Reply on Twitter 1557462517701558274 Retweet on Twitter 1557462517701558274 2 Like on Twitter 1557462517701558274 4 Twitter 1557462517701558274

Follow @POGO4Kids

Quick Links

  • For Professionals
    • Read Cancer Care Plan
    • Review our Guidelines
    • Request Research Data
  • Families & Kids
    • Get POGO AfterCare
    • Meet with a POGO Nurse
    • Get Care Closer to Home
  • For Survivors
    • Find Local Resources
    • Set Goals for your Future
    • Educate Yourself
  • Get Involved
    • Host an Event for POGO
    • Volunteer with POGO
    • Partner with POGO
  • About Us
    • Our Mission and Vision
    • Childhood Cancer Care Plan
    • POGO Land Acknowledgement
    • Diversity, Equity, Inclusion
    • Our Board
    • Our Partners
    • Our Donors
    • Privacy
    • Accessibility
    • Reports
    • Newsroom
    • Job Opportunities
    • Staff List
  • Programs & Support
    • Patient Care Programs
    • Financial Assistance
    • Survivor Care
    • Cancer Resources
    • Inspiring Stories
    • Clinical and Program Advisory Committees
  • Education
    • POGO Multidisciplinary Symposium on Childhood Cancer
    • POGO Virtual Education
    • Indigenous Resource Guide
    • All Education Events & Conferences
  • Healthcare Practice
    • COVID-19 Updates
    • Pediatric Oncology Nursing
    • Clinical Practice Guidelines
    • POGO Satellite Manual
  • Research & Data
    • 2020 POGO Surveillance Report
    • POGO Research Unit
    • POGONIS – Childhood Cancer Database
    • Data Reports
    • Data Requests
  • Get Involved
    • Pajamas and Pancakes
    • Birthday Parties for POGO
    • Events
    • Volunteer
  • Ways to Give
    • Donate
    • Gifts of Stock and Securities
    • Become a Corporate Partner
    • Gifts in Honour/Memory
    • Legacy Gifts
    • Shop Online/Earn Cash Back

©2022 Pediatric Oncology Group of Ontario

480 University Avenue, Suite 1014 | Toronto, Ontario, M5G 1V2, Canada | Charitable Registration Number: 871067245RR0001 |
1-855-FOR POGO (367-7646) | Contact Us | Website Privacy Policy | Website Disclaimer | Satellite Manual Disclaimer |